Skip to main content
AAN.com
WriteClick® Editor's Choice
July 10, 2017

Author update: Sarcoplasmic MxA expression: A valuable marker of dermatomyositis

Abstract

Soon after our article published,1 we learned the sale of the myxovirus resistance A (MxA) polyclonal antibodies used in the study (Mx1/2/3 [H-285], sc-50509, Santa Cruz Biotechnology, Dallas, TX) had been discontinued. Furthermore, we received inquiries from several physicians concerning alternate MxA antibodies. We tested the company's monoclonal antibody alternate (Mx1/2/3 [C-1], sc-166412) on frozen muscle sections at various dilutions in 2% bovine serum albumin in PBS using the Ventana immunohistochemistry detection system (Ventana Medical Systems, Tucson, AZ) with or without the enhancement mode. Muscle samples tested included MxA-positive dermatomyositis (n = 3, including 1 juvenile participant), MxA-negative dermatomyositis (n = 3), anti-Jo-1 myopathy (n = 3, MxA-negative), and immune-mediated necrotizing myopathy (n = 3, comprising 1 with anti-signal recognition particle antibodies [MxA-negative], 1 with anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies [MxA-negative], and 1 without those antibodies [MxA-positive]). We observed essentially the same staining pattern at comparable signal intensity as the original polyclonal antibodies at 1:10 dilution with the enhancement mode although the signal was barely detected at the manufacturer's recommended dilution (starting dilution: 1:50), indicating that the monoclonal antibody alternate can be similarly used to detect sarcoplasmic MxA expression on frozen muscle sections for the diagnosis of dermatomyositis (although higher concentration is necessary).

Get full access to this article

View all available purchase options and get full access to this article.

Reference

1.
Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology 2017;88:493–500.

Information & Authors

Information

Published In

Neurology®
Volume 89Number 2July 11, 2017
Pages: 215
PubMed: 28696934

Publication History

Published online: July 10, 2017
Published in print: July 11, 2017

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Updates on the Immunopathology in Idiopathic Inflammatory Myopathies, Current Rheumatology Reports, 23, 7, (2021).https://doi.org/10.1007/s11926-021-01017-7
    Crossref
  2. Distinct Histopathologic Patterns of Finger Eruptions in Dermatomyositis Based on Myositis-Specific Autoantibody Profiles, JAMA Dermatology, 155, 9, (1080), (2019).https://doi.org/10.1001/jamadermatol.2019.1668
    Crossref
  3. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis, Neuropathology and Applied Neurobiology, 45, 5, (513-522), (2018).https://doi.org/10.1111/nan.12519
    Crossref
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share